Ephedra & stroke
This article was originally published in The Tan Sheet
"Association between the use of ephedra-containing products and increased risk for hemorrhagic stroke" was not demonstrated in Hemorrhagic Stroke Project, L.B. Morgenstern, MD, University of Texas at Houston, et al., report in the January issue of Neurology. However, researchers note "analysis by dose suggests there may be an association with use of more than 32 mg/d" ephedra. Morgenstern et al. analyzed 702 subjects who enrolled between December 1994 and July 1999 in the HSP, which was designed to investigate association between phenylpropanolamine and hemorrhagic stroke risk. HSP findings eventually prompted FDA to request PPA marketers pull the ingredient off the market...
You may also be interested in...
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
The leadership of top Indian firms recounted at the IPA Forum how they got together on a joint 45-minute call daily in the early phase of the pandemic to collaborate and ensure uninterrupted supplies of medicines both in India and globally. The executives also shared views on telemedicine and digitalization trends at the event.
Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.